Children are more susceptible to exposures in utero and during early childhood that may result in developmental problems and chronic diseases. Novel discoveries in the field of molecular epidemiology that can help explain susceptibility to exposures and disease will be demonstrated using the multifunctional enzyme paraoxonase 1 (PON1) as an example.
INTRODUCTION
Paraoxonase 1 (PON1) is an enzyme involved in oxidant defense by hydrolyzing oxidized lipids [1] and also plays a key role in the detoxification of some organophosphate pesticides [2] . Thus, individuals with low PON1 levels and activities may be more susceptible to organophosphate exposures and oxidative stress, which occurs when there is an excess of damaging reactive oxygen species. PON1 genetic variants and lower enzyme levels have been linked to adverse health outcomes including oxidative stress-related conditions such as cardiovascular disease and obesity [3] [4] [5] [6] [7] . Therefore, it is of considerable clinical interest to characterize the protective role of endogenous antioxidant enzymes against the development of obesity and metabolic syndrome (MetS) in children. Previous reviews of PON1 research have shown that age and genetics are key factors associated with PON1 variability and, thus, susceptibility. Here, we highlight novel developments in PON1 research including epigenetic mechanisms such as DNA methylation and noncoding RNAs, as well as the effects of genetic admixture, especially important for studies of minority populations, and the relationship of genetic and epigenetic markers with obesity and metabolic disease.
Human PON1 enzyme is a 43kDa protein composed of 354 amino acids. It is referred to as a multifunctional enzyme because it can metabolize a number of substrates including some oxon forms of organophosphate pesticides (this is where the name paraoxonase originates from) and aryl esters, among others. Spectrophotometric methods have been established for the most commonly used substrates for the measurement of PON1 molecular phenotype. These include phenyl acetate and paraoxon, which measure arylesterase (AREase) and paraoxonase (POase) activity, respectively. AREase activity is considered an indirect measure of PON1 protein level and has been highly correlated with western blot and ELISA experiments [8, 9] . POase activity reflects both quantity and catalytic efficiency of the enzyme.
More recently, several studies have demonstrated that the native substrates for PON1 are likely lactones [10] and researchers are now beginning to incorporate the use of lactonase substrates such as dihydrocoumarin [11 && ] and 5-thiobutyl butyrolactone (TBBL) in PON1 experiments [11 && ,12 && ,13]. For instance, Ferre et al. [12 && ] found that TBBLase, but neither POase nor PON1 concentrations, determined by ELISA, was significantly associated with obesity status in prepubertal and adolescent children (age 9-15 years) as well as several obesity markers such as BMI, body fat percentage, and triglyceride levels (Table 1) . Obese children with MetS had even lower levels of TBBLase than obese children who did not have MetS [12 && ]. As lactones are the endogenous target of PON1, lactonase activity may be an important and relevant marker of PON1 molecular phenotype particularly for studies related to oxidative stress rather than organophosphate pesticide exposure.
The polymorphic PON1 gene is a member of the PON family cluster of genes including PON1, PON2, and PON3, which all reside adjacent to each other on chromosome 7. PON1 specifically has been mapped along the chromosome 7q21.3-22.1 region [17, 18] and contains nine exons. Over 200 gene variants have been identified in the PON1 gene; however, only a few promoter single nucleotide polymorphisms (SNPs) significantly influence protein levels as measured by AREase activity [19] [20] [21] [22] [23] . In particular, rs705379 (PON1 -108 ), is the strongest predictor of AREase activity. Furthermore, the PON1 -108CC genotype is associated with two-fold higher PON1 enzyme levels compared with the PON1 -108TT genotype [24, 25] . The SNP at the position 192 (rs662) in the coding region impacts the catalytic efficiency of the enzyme in detoxifying organophosphate pesticides with the PON1 192QQ genotype coding for the enzyme with the lowest efficiency [26] . A number of studies have examined the association of numerous PON1 SNPs with PON1 molecular phenotype but the majority of SNPs do not explain a substantial amount of additional variation of enzyme quantity or activity in comparison to the commonly studied PON1 -108 and PON1 192 SNPs [22, 27] . One recent study identified a few rare PON1 variants and some transacting variants located in the FTO and SER-PINA12 genes that displayed a modest association with AREase activity independent of common PON1 SNPs [28] . However, these associations were not as strong as those with previously identified PON1 SNPs.
Although most studies of PON1 focus on just a small set of the most common PON1 SNPs, one recent study characterized 16 PON1 genetic variants and their relationship with several different substrate-specific activities, including lactonase (using dihydrocoumarin substrate), POase, AREase, and diazoxonase (DZOase) activities in prepubertal children (ages 4-16 years) [11 && ]. The relationships of these SNPs with the different substrate-specific PON1 activities were highly dependent on their location in the gene. For instance, promoter region SNPs were highly associated with AREase, lactonase, and DZOase, whereas 3' untranslated SNPs were more strongly associated with POase and less
KEY POINTS
The broad variability of PON1 levels and activities in humans can confer differential susceptibility because this multifunctional enzyme can detoxify organophosphate pesticides and has antioxidant properties.
Genetics and age are strong determinants of PON1 variability and, therefore, susceptibility to oxidative stress and organophosphate exposure.
Epigenetic modifications such as DNA methylation and miRNAs may provide additional insights into the mechanisms of PON variability.
In addition to commonly used measurements for PON1 status, as well as AREase and POase activity, future studies of PON1 function may be enhanced by incorporation of lactonase activity as a reliable indicator of PON1 phenotype.
In order to use PON1 as a model to predict risk of obesity and other health outcomes, it should integrate enzyme activities, genetic and epigenetic factors, and take into account genetic ancestry as a potential confounding factor. associated with other substrate-specific activities. Interestingly, Ruperez et al. [11 && ] also identified an intronic SNP, rs854566, which was inversely associated with obesity and also significantly associated with all four substrate-specific activities measured. None of the PON1 activities differed between obese and nonobese children; however, lactonase activity was correlated with markers involved in lipid metabolism like high density lipoprotein and ApoA1 [11 && ]. Several studies have demonstrated that PON1 status, which includes measures of both PON1 192 genotype, which affects catalytic efficiency toward some substrates, and protein levels (AREase assay), may be a more comprehensive descriptor of PON1 molecular phenotype and a more accurate predictor of disease [17, 29, 30] .
OTHER GENETIC EFFECTS: ADMIXTURE AND ANCESTRY INFORMATIVE MARKERS
In genetic association studies of admixed populations, heterogeneity of genetic background can lead to spurious associations if ancestry is related to both a candidate gene and the disease outcome of interest ( Fig. 1a ); this is also referred to as genetic confounding due to population stratification [31] . Structured association methods enable us to adjust for potential genetic confounding. This is done by genotyping a number of ancestry informative markers, genetic variants known to vary widely between different ethnic groups, and using the known frequencies among reference populations to estimate proportion of ancestry in individuals. The estimated parameters can then be included in statistical models as covariates. Figure 1b [32] . Ancestral distributions range quite broadly within populations in both studies and between populations for GALAII.
Both functional PON1 genetic variants PON1 192 and PON1 -108 , among others, vary substantially among ethnic groups. For instance, the frequency of the Q allele for the PON1 192 SNP is 0.73 for Caucasians [33] , 0.37 for African-Americans [33] , and 0.48 for Mexicans [21, 34] . Furthermore, many of the oxidative stress-related health outcomes ranging from birth weight to obesity and cardiovascular disease differ in prevalence by ethnic groups, making genetic ancestry an important factor to consider in PON1 studies, especially in admixed populations. We recently examined associations of PON1, obesity, and genetic ancestry in young Mexican-American children [15 && ]. Although a trend of higher African ancestry with higher BMI z-scores and odds of obesity was observed, these relationships did not reach statistical significance after adjusting for multiple testing. We also identified a strong increased odds of obesity in children with the PON1 192QQ genotype at ages 2 and 5 and found similar trends in relation to waist circumference at age 5. After controlling for genetic ancestry, this relationship with PON1 192 genotype remained, although beta coefficients changed moderately (9-15%), demonstrating suggestive evidence of genetic confounding by population stratification. Presence of genetic confounding may explain some of the inconsistencies between reported studies as it can introduce bias, yet to our knowledge, few other studies have attempted to adjust for population stratification in PON1 genetic association studies [11 
PARAOXONASE EPIGENETICS
PON1 genetics does not completely explain the broad variability of PON1 molecular phenotype and other factors should be considered. There is a growing recognition that epigenetics may play an important role in key biological processes and mechanisms of disease development [36] [37] [38] . Epigenetic mechanisms regulate gene expression without changes in DNA sequence and include DNA methylation, histone modifications, and noncoding RNAs [39] [40] [41] . Here, we focus on DNA methylation and microRNA (miRNA) because, in contrast to chromatin modification assays that are mainly qualitative and require large sample volumes, the stateof-the-art methodologies available for these marks are more amenable to human population studies. Furthermore, a 2011 review of PON1 research describing potential regulators of PON1 expression highlighted epigenetics as an unexplored field [42] .
DNA methylation is the most extensively investigated epigenetic mechanism and refers to the potential of a cytosine (C) base to be methylated at its fifth carbon if followed by a guanine (G) base in the DNA code, called a CpG site. The human genome contains about 30 million CpG sites. CpG sites are distributed throughout several regions of the genes referred to as CpG islands, shores, shelves, and gene bodies. CpG islands are stretches of DNA with a high frequency of CpG dinucleotides that often occur in proximity to gene promoter regions [43] . It was previously believed that the majority of functional changes occurred in CpG islands, but new research has shown that DNA methylation changes along CpG shores (regions within 2 kb of islands) and within the gene body may also have functional effects on gene expression [44, 45] . The amount and patterns of DNA methylation are established during the prenatal period and may vary by tissue and cell type [46, 47] . Gain or loss of DNA methylation, referred to as hypermethylation and hypomethylation can lead to gene silencing or overexpression, respectively [48] .
The PON1 promoter has one CpG island comprising 19 CpG sites with a second island located near exon 7 (eight CpG sites). There are a total of 287 CpG sites in PON1 including 66, 48, and 146 CpG sites within shores, shelves, and other regions referred to as the open seas, respectively (Fig. 2) . Data on PON1 methylation are scarce. Only one study has examined associations between PON1 methylation at several CpG sites with molecular phenotype [49 && ]. De la Iglesia et al. [49 && ] reported an inverse association between methylation levels of several promoter region CpG sites and AREase activity in 47 adults with MetS in an energyrestricted dietary weight-loss intervention. This relationship was strongest for CpG sites that were closest in proximity to the PON1 transcription start site. Additionally, a parallel decline in AREase activity was seen with decreases in several obesityrelated parameters such as BMI, fat mass, blood pressure, and triglyceride levels. Another small study of 24 adults also reported an association between methylation at two PON1 promoter CpG sites with body weight and waist circumference, providing further evidence that PON1 DNA methylation may influence obesity risk [50] .
Another class of epigenetic marks includes miRNAs, which are small ($23 nucleotide) noncoding RNAs that regulate gene expression by pairing with protein-coding mRNAs and directing their posttranscriptional repression. To date, approximately 2500 miRNAs have been identified in humans; however, the majority of their target-binding sites are not yet known [51] . Putative-binding sites within coding sequences can be identified by sequence complementarity to candidate miRNAs [52] . MiRNAs regulate protein expression by the cleavage of homologous mRNA or by specific inhibition of translation. It is estimated that 10-30% of human protein-coding genes are targets of miRNA binding [53] , and aberrant expression of miRNA has been implicated in numerous diseases [54, 55] . MiR-NAs are an excellent epigenetic biomarker to study for the following reasons: they are ubiquitously expressed in tissues and body fluids including blood, urine, and saliva; as miRNAs are released into the bloodstream from target tissues (i.e., brain, liver) circulating miRNAs may reflect profiles of target tissue [56] ; and they are highly stable and resistant to RNase activity as well as effects of pH and temperature in stored specimens over time [55] .
In-silico analyses using miRanda software (Memorial Sloan Kettering Cancer Center, New York, NY), and considering conservation and good support vector regression (SVR) scores, have yielded 25 putative miRNA binding sites in the PON1 3' untranslated region (Fig. 2) . One recent study showed that a PON1 SNP located in a different miRNA binding site (miR-616) was associated both with changes in PON1 expression and increased risk of ischemic stroke and carotid atherosclerosis [57 && ]. Unlike the other putative miRNAs that may target PON1, this is the only miRNA that has been functionally validated and shown by reporter assay to bind PON1. Furthermore, Liu et al. [57 && ] were able to show that the PON1 SNP, rs3735590, affected the binding affinity of miR-616 to PON1 and resulted in differences in PON1 expression. These data demonstrate the molecular mechanisms through which the interplay of genetics and epigenetics influence PON1 expression and demonstrate further the clinical significance of PON1 variability. Although the complex interactions between DNA methylation, miRNAs, and genetics are not yet well understood, recent data suggest that miRNA gene expression can also be regulated by aberrant DNA methylation of miRNA genes [58] [59] [60] [61] .
PARAOXONASE, OBESITY, AND METABOLIC SYNDROME
Few studies have examined the associations of PON1 substrate-specific activities or genotypes with obesity or MetS in children; however, this field of research has grown substantially over the past 2 years (Table 1) . AREase activity, a marker of PON1 enzyme quantity, was inversely associated with obesity status [62] and waist circumference [16 & ] in two studies of children and adolescents. Yet one study of older children in Spain, which measured PON1 concentration by ELISA [12 && ], and our study in 2-year-old Mexican-American children [15 && ] found positive associations of PON1 quantity with obesity. Interestingly, at age 5, we found that AREase activity was inversely associated with obesity status in PON1 192QQ but not PON1 192RR children, indicating the associations with obesity can change with age and by genotype [15 && ]. Lactonase (TBBLase) and PON1-specific activity (POase divided by PON1 concentration) were also inversely associated with several obesity parameters (BMI, % body fat) in children [12 && ]. The only other study to examine lactonase activity using dihydrocoumarin did not observe associations of lactonase or other substrate-specific activities with obesity in prepubertal children, but did report a relationship of lactonase activity with lipid profiles [11 && ]. Two studies, including ours, found higher BMI z-scores, waist circumference, and odds of obesity with the PON1 192Q allele in young children [15 && ] as well as school-age children [14] . However, some studies did not observe the same relationship [ ] also examined associations with haplotypes, which incorporate combinations of multiple SNPs on a single chromosome [63] . Nevertheless, based on our study [22] and recent publications that also examined PON1 haplotypes [11
&&

,12
&& ], there is no apparent advantage in using haplotypes in the analysis of PON1 effects.
PERSPECTIVES
Although findings have been inconsistent, a number of studies have identified potential relationships between PON1 genetic variants and substrate-specific activity with obesity and MetS. Several factors may help to explain differences observed between studies. First, most studies included participants with large age ranges (more than 2 years) but did not adjust for age in their analyses with substrate-specific activities even though it has been shown that PON1 levels and activities increase with age through at least age 7 [64, 65] . Additionally, it is possible that the relationship of PON1 with obesity may differ by age. Another important difference between studies was the ethnic composition of the populations included, which may be particularly relevant because allele frequencies of many common PON1 SNPs vary so widely between ethnic groups. For future studies, it will be important to adjust for potential confounding by population stratification in PON1 studies related to obesity, particularly in admixed populations. Finally, it should be pointed out that no studies of children's obesity have looked at the relationship of PON1 epigenetics with obesity despite solid preliminary evidence that DNA methylation and miRNAs may affect PON1 variability. Liu et al. [57 && ] demonstrated that the complex interactions between genetics and epigenetics are an important molecular mechanism that affects PON1 expression and important oxidative stress-related health outcomes in adults. Overall, incorporation of novel emerging methodologies and analyses, such as epigenetics, lactonase activity, and control for genetic confounding, into PON1 research may help to further characterize molecular mechanisms affecting PON1 variability and susceptibility to organophosphate exposure and oxidative stress-related health conditions. CONCLUSION PON1 serves an important example of a susceptibility factor, whose characterization can help us to understand the cause of multiple diseases. Here we have highlighted several methodologies that may broaden the scope of PON1 research and help to explain some of the molecular mechanisms linking PON1 to disease. More generally, many of these concepts can be applied to other susceptibility markers involved in metabolism, inflammation, or other important biological pathways. Identifying the factors that modulate gene expression, accounting for differences in study populations, and trying to assess the complex interplay of different molecular markers (genetics, epigenetics, enzyme levels, etc.) may increase our understanding of these susceptibility markers. This is essential for elucidation of the cause of complex diseases in children and reliable interpretation of data used for personalized medicine.
